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A B S T R A C T
Background: Autologous donor skin harvested for transplantation is a common procedure in patients
with burns, and patients often feel more pain at the donor site than is justiﬁed by the extent of trauma.
Topical morphine gels have been thought to have an effect on peripheral opioid receptors by creating
antinociceptive and anti-inﬂammatory effects, which could potentially reduce the systemic use of morphine-
like substances and their adverse effects.
Methods: We therefore did a paired, randomised, double-blind placebo study to investigate the effect
of morphine gel and placebo on dual donor sites that had been harvested in 13 patients. Pain was mea-
sured on a visual analogue scale (VAS) 15 times in a total of 5 days.
Results: The mean (SD) VAS was 1.6 (2.3) for all sites, 1.5 (2.2) for morphine, and 2.0 (2.5) for placebo.
The pain relieving effects of morphine gel were not signiﬁcantly better than placebo.
Conclusion: The assessment of pain at donor sites is subjective, andmore systematic and objective studies
are needed.
© 2016 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Autologous split-thickness skin grafts (STSG) harvested with a
dermatome are widely used for transplantation in deep burns, large
wounds, cell harvesting for keratinocyte retransplantation and other
reconstructive procedures. Numerous studies have been pub-
lished on the optimal dressing and management of pain at donor
sites [1–15]. Clinical experience has suggested that patients often
feel more pain than is justiﬁed by the extent of trauma [1–3,16].
Pain can give rise to adverse effects such as hypertension and ag-
itation, and can impair wound healing [16,17]. High doses of
analgesics such as morphine or morphine-like substances are often
used to alleviate it. Unfortunately, the systemic use of opioids can
cause many adverse effects such as respiratory depression, nausea,
pruritus, and constipation [18,19].
1.1. Topical treatment for peripheral pain control
Topical treatments are available as gels, creams, ointments, lotions,
solutions, pastes, sprays or patches [20]. Non-opioid treatment for
pain at donor sites has focused on analgesics such as lignocaine or
bupivacaine with some success [5,7,8,17]. Authors have suggested
that some dressings not only affect healing, but also reduce pain
at the donor site better than others [1,4,6,9–12,21,22]. Topical opioids
applied to wounds in the cornea, the oral mucosa, and to various
types of wounds in the skin have had mixed results [23–30]. Al-
thoughmost pain-relieving topical treatments are intended to induce
analgesia locally, it can sometimes be diﬃcult to distinguish pe-
ripheral effects from systemic effects [13,24,29,31–33].
1.2. Molecular mechanisms of peripherally applied opioids
Since the discovery and characterisation of peripheral opioid re-
ceptors, many studies have shown that the analgesic effects of opioids
can also bemediated by peripheral receptors. After diffusion through
the skin, topical opioids produce analgesia by their agonistic effects
on opioid receptors on injured peripheral sensory neurons. This
creates conformational changes that allow the intracellular
Abbreviations: OD, operation day; POD, postoperative day; RCT, randomised con-
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coupling of signalling proteins to the receptors and their subse-
quent interaction with ion channels in the membrane. In turn this
reduces the excitability of nociceptive neurons and lessens the release
of pronociceptive neuropeptides. All these events lead to
antinociceptive and anti-inﬂammatory effects [34,35].
1.3. Study rationale
We aimed to study the eﬃcacy of topically applied morphine
gel on pain at the donor site. In a previous randomised study that
examined the use of topical opioid gel at donor sites, no signiﬁ-
cant differences were found, but it did not address the issue of
potential antinociceptive effects that last for more than 24 hours
postoperatively [13]. The potential anti-inﬂammatory effects of
topical opioids might contribute to the prolongation of their pain-
relieving action [34–37], which creates the need to study pain scores
for longer periods after initial application. We therefore con-
ducted a clinical trial to study the possible pain-reducing effect of
topically applied morphine gel at the donor sites of split thickness
skin grafts (STSG) for 5 days after operation.
2. Material and methods
This prospective, paired, randomised, double-blinded, placebo-
controlled trial was approved by the regional local ethics committee
(Linköping University, Dnr 00–047), and it conforms to the Hel-
sinki Declaration of 1975 (revised in 2000). It is also designed to
try to adhere to CONSORT criteria for randomised controlled studies
(RCT). The study included male and female patients over 18 years
of age with burns who were listed for STSG with planned harvest
of skin from the thigh at Linköping University Hospital Burn Center.
Informed consent had been obtained orally and in writing. Those
with known severe adverse effects to morphine or other opioid-
like substances were excluded. Grafts were harvested with a
dermatome according to clinical routine. Donor sites with similar
sizes were paired and located either on each leg or, if only one leg
was used, medially and laterally or ventrally and dorsally. Donor
sites were randomised for active or placebo treatment. Each patient
was given one application of active or placebo gel of 2 ml each in
syringes marked 1 and 2 directly after skin graft harvesting. The gel
was not visually distinguishable from each other; both patient and
caregiver were blinded to the study. The wound was then dressed
with a polyurethane foam dressing (Allevyn, Smith and Nephew)
and elastic wrap. Patients then assessed the intensity of pain from
each donor site 3 times a day for 5 consecutive days using a visual
analogue scale (VAS) (0: no pain at all to 10: worst pain imagin-
able). Systemic analgesics (oral or parenteral, or both) were given
when needed (Fig. 1).
The gel was obtained from Apoteket Production and Laborato-
ries (APL) (Stockholm, Sweden) as a sterile hydrogel containing
hydroxypropyl methylcellulose (a semisynthetic, inert viscoelastic
polymer) andmorphine hydrochloride 1mg/ml. The placebo gel was
made in a similar way using the same components except mor-
phine. The gels were sent from the hospital pharmacy in identical
syringes labelled “Gel 1” and “Gel 2”.
2.1. Statistical analysis
To analyse the differences in VAS between the 2 groups, we used
Wilcoxon signed-rank test, normality tests, and paired Student’s
t-test. Box plots, descriptive statistics, and bar charts were done using
Stata SE for Mac OS (Version 12.0, StataCorp College Station, USA).
Area under the curve (AUC) measurement was done using Microsoft
Excel forMac OS (Version 14.0.0, Microsoft Redmond Campus,Wash-
ington, US) and was constructed using the trapezoid method with
linear interpolation of missing values between 2 valid points. The
Wilcoxon signed-rank test was done to compare the mean of the
2 groups. Probabilities are two-tailed and those of less than 0.05
were considered signiﬁcant. Results were analysed daily and for the
whole group. Data are presented as mean (SD) if not otherwise
speciﬁed.
3. Results
We used data from 13 patients (3 women and 10 men), mean
age 53.3 years (range 20–85) (Table 1, Fig. 1). Analysis was made
for originally assigned groups. The donor site was measured during
operation to be about 8–9 cm wide and 15–20 cm long. The graft
was about 10–12/1000″ inches thick. No individual measure-
ments were collected for analysis. No adverse events were reported.
Some VAS assessments were missing, and blank time points were
excluded from pairedmean comparison tests. Missing values outside
valid points were ignored.
Mean values were calculated for each time point for each patient.
The mean (SD) VAS was 1.6 (2.3) for all sites, 1.5 (2.2) for mor-
phine, and 2.0 (2.5) for placebo. The Wilcoxon signed-rank test
showed that differences in the assessment of pain between the 2
groups were not signiﬁcant (Table 2, Fig. 2). Data were tested for
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Fig. 1. Flow diagram of study design and execution.
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normality and subsequent paired t-tests also showed no signiﬁ-
cant differences between the groups. We found no signiﬁcant
differences when we compared AUC using non-parametric com-
parison tests (Table 2, Fig. 2). This was the case for all days or split
into individual days. Clinical confounders could not be veriﬁed or
discarded because of the small sample size.
4. Discussion
Pain at STSG donor sites is an important clinical problem. It is
often described as being more severe than at the grafted site [1–3]
[16] and empirical observations from our burns centre support this.
Datawere considered normally distributed but normal t-tests, non-
parametric tests, and comparison of AUC showed no signiﬁcant
differences. We had to modify AUC comparisons through interpo-
lation, as missing values increase bias. The modiﬁcation lowered
the risk for bias but was not fully satisfactory [38]. There was no
difference between the groups after operation or during the 4 post-
operative days. It could be speculated that a larger studywithmore
patients might show signiﬁcant results. No previous power calcu-
lation was made to estimate sample size (Table 2, Figs 2 and 3).
4.1. Molecular mechanisms and clinical deductions
Studies have shown that the proximal perineural application of
opioids along non-injured nerves does not produce reliable anal-
gesic effects. To obtain a pronounced and sustained analgesic effect,
a combination of injured nerves and endogenously-released pep-
tides is required [34,35]. It is generally thought that nerves in the
skin are cut or damaged, or both, when the upper part of the epi-
dermal and dermal layers are harvested, which led us to speculate
about the use of topical morphine for pain relief. However, we found
that it had no signiﬁcant effect.
Topical opioids might also have anti-inﬂammatory effects. The
number of peripheral opioid mechanisms of pain control increases
with the duration and severity of inﬂammation, and inﬂammation
further contributes to the antinociceptive effects of opioids through
multiple intracellular and extracellular signalling effects [34,35]. Par-
adoxically, this might indicate that topical morphine has a limited
effect immediately after injurybut abetter effect lateron in thehealing
process, so we continued to assess pain for 5 consecutive days.
However, we did not observe any delayed analgesic effect.
4.2. Potential pain-relieving effects of gels and systemic treatment
of pain
In contrast to our own clinical experience, we report less pain
from the donor sites regardless of treatment. Our results show that
the patients reported a VAS of 3 or more in only 17.8% of all time
Table 1
Clinical data on patients. No adverse events were reported.
Patient no. Sex Age Placebo Morphine
1 F 23 L, med. L, lat.
2 F 81 L, ant. R, ant.
3 M 74 R, lat.ant. R, med.ant.
4 M 63 R, med. R, lat.
5 M 85 L R
6 M 82 R L
7 M 38 R, lat. R, med.
8 F 20 R, lat. R, med.
9 M 51 L, ant. L, post.
10 M 39 lat. med.
11 M 63 L, med. R, lat.
12 M 36 L R
13 M 38 L, post. R, post.
Mean 3 F, 10M 53.3
Table 2
Visual analogue scores (VAS) for use of morphine gel and placebo gel, divided by groups.
Observations Mean
Placebo
Mean,
morphine
gel
Mean
difference
Wilcoxon
paired
sign-rank
test, p =
AUC comparison
using Wilcoxon
paired sign-rank
test, p =
All 129 1.95 1.48 0.47 0.26 0.22
OD 17 2.14 1.02 1.17 0.09 0.33
POD 1 32 2.08 1.75 0.33 0.5 0.17
POD 2 30 1.85 1.47 0.28 0.28 0.12
POD 3 30 1.67 1.31 0.37 0.48 0.49
POD 4 20 2.89 2.19 0.7 0.08 0.08
OD, operative day; POD, postoperative day.
0
2
4
6
8
10
12
Morphine gel Placebo gel
VAS
Fig. 2. Box plot comparing VAS pain scores of morphine gel compared with placebo gel showing different quintiles and outliers.
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points. It could be argued that the inert gel-base could be in-
volved in the reduction of pain but a more plausible explanation
is the use of concurrent systemic analgesia (the dosagewas not docu-
mented). Using only polyurethane foam on donor sites (mean area
of 68.8 cm2), Lauchli et al. reported a mean VAS of 0.75 on day 1
and 0.53 on day 5 [14]. Weber et al. used the same polyurethane
foam as we did and reported a mean VAS of 0.8 on day 1 and 2.0
on day 5 with a mean donor site area of 89.2 cm2 [15]. In compar-
ison, these results measuring donor site pain are not considerably
higher than those reported in our study.
4.3. Intensity of pain at the donor site
The intensity of pain at the donor site is a matter of debate as
it is clinically perceived to be high in comparison with the extent
of surgical trauma. However, to our knowledge few clincal studies
have focused on pain and have compared different wound dress-
ings instead.Weber et al. showed that the VAS for donor sites dressed
with polyurethane foam was lower than that for the operative site
[15]. Arigova et al. compared Acticoat (Smith and Nephew) with
Allevyn (mean VAS 2.33 and 3.33, respectively, at day 4). They re-
ported higher mean pain scores than those in our study but the VAS
had been measured when the dressings were changed [4]. Barnea
et al. compared Aquacel (ConvaTec) with paraﬃn gauze (VAS 3.5
and 2.4, respectively at day 1) and reported higher pain scores than
those in our study [1]. When Akan et al. compared conventional har-
vesting of grafts with use of overlying skin ﬂaps, they reported pain
scores with a mean VAS of 5.87 on day 1, which is considerably
higher than our ﬁndings and more in line with that which
is clinically perceived [2]. In a study of wounds dressed with
Surgicel (Ethicon) or ﬁne meshed gauze treated with Furacin
(GlaxoSmithKline), Uysal et al. reported no pain in 50% and 18.7%,
respectively, of the groups [3]. Simultaneous use of systemic pain
relief or the choice of anaesthetic during operation are important
confounders in studies on pain at donor sites and are not always
reported in detail.
4.4. Study limitations and ﬁnal remarks
In a randomised, placebo study in which different uniform doses
of 0.25 mg, 0.75 mg, and 1.25mg/100 cm2 were given, there was no
signiﬁcant difference between morphine and placebo [13]. Further
studies need to be done to evaluate the optimum dosage/cm2 or
whether it should be based on the surgeon’s preference.
We did not collect data on healing time with or without use of
the gel, or patients’ coexisting conditions, whichmight affect healing
and the subjective evaluation of pain. Given the rapid action of mor-
phine, closer time points for measurement might give more detailed
information on its effects. Also, it would be interesting to study the
effects of repeated applications over several days.
We did not detect any adverse events, but more studies need to
be done with a larger sample and over longer periods of time to
conﬁrm the reliability and non-toxicity of the morphine gel.
5. Conclusions
We found that topical opioid gel does not reduce pain signiﬁ-
cantly at the donor site after harvest of STSG, and its pain-relieving
effects up to 4 days after operation are not signiﬁcantly better than
placebo. Future studies are needed (preferably with larger sample
size) to examine the effect of topical opioids and to further our un-
derstanding of pain at the donor site.
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